CoChat

Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β

Open access

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Nonalcoholic fatty liver disease (NAFLD) is now the most common progressive liver disease in developed countries and is the second leading indication for liver transplantation due to the extensive fibrosis it causes. NAFLD progression is thought to be tied to chronic low-level type 1 inflammation originating in the adipose tissue during obesity; however, the specific immunological mechanisms regulating the progression of NAFLD-associated fibrosis in the liver are unclear. To investigate the immunopathogenesis of NAFLD more completely, we investigated adipose dysfunction, nonalcoholic steatohepatitis (NASH), and fibrosis in mice that develop polarized type 1 or type 2 immune responses. Unexpectedly, obese interleukin-10 (IL-10)/IL-4-deficient mice (type 1-polarized) were highly resistant to NASH. This protection was associated with an increased hepatic interferon-γ (IFN-γ) signature. Conversely, IFN-γ-deficient mice progressed rapidly to NASH with evidence of fibrosis dependent on transforming growth factor-β (TGF-β) and IL-13 signaling. Unlike increasing type 1 inflammation and the marked loss of eosinophils seen in expanding adipose tissue, progression of NASH was associated with increasing eosinophilic type 2 liver inflammation in mice and human patient biopsies. Finally, simultaneous inhibition of TGF-β and IL-13 signaling attenuated the fibrotic machinery more completely than TGF-β alone in NAFLD-associated fibrosis. Thus, although type 2 immunity maintains healthy metabolic signaling in adipose tissues, it exacerbates the progression of NAFLD collaboratively with TGF-β in the liver.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aal3694

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 143

Metadata

Authors
Hart, K. M., Fabre, T., Sciurba, J. C., Gieseck, R. L., Borthwick, L. A., Vannella, K. M., Acciani, T. H., de Queiroz Prado, R., Thompson, R. W., White, S., Soucy, G., Bilodeau, M., Ramalingam, T. R., Arron, J. R., Shoukry, N. H., & Wynn, T. A.
Affiliations
  • National Institutes of Health (US)
  • Centre Hospitalier de l’Université de Montréal (CA)
  • Newcastle University (GB)
  • Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal, Québec, Canada.
  • Genentech (US)
Corresponding author
Wynn, Thomas A.
Venue
Science Translational Medicine
Published
2017-06-28
Volume
9
Issue
396
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W2724672633
Cited by
143
References
55
Citations by year
2026: 11 · 2025: 16 · 2024: 15 · 2023: 16 · 2022: 17 · 2021: 13 · 2020: 19 · 2019: 16 · 2018: 14 · 2017: 6
FWCI
11.78
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
NIH Office of the Director (award305255)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
non-alcoholic fatty liver disease, Th2 immune response, TGF-beta, IL-13, liver fibrosis, nonalcoholic steatohepatitis, interferon-gamma, eosinophils, adipose tissue dysfunction, obesity, immunopathogenesis, metabolic disorders
MeSH terms
Adipose Tissue, Animals, Eosinophils, Humans, Immunity, Inflammation, Interferon-gamma, Liver Cirrhosis, Male, Metabolic Diseases, Mice, Inbred C57BL, Obesity, Transforming Growth Factor beta, Disease Progression, Diet, High-Fat, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.